Copyright Reports & Markets. All rights reserved.

Global Epilepsy Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Epilepsy Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Epilepsy Drug Market Size Growth Rate by Product
      • 1.4.2 First Generation Drugs
      • 1.4.3 Second Generation Drugs
      • 1.4.4 Third Generation Drugs
    • 1.5 Market by End User
      • 1.5.1 Global Epilepsy Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Research
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Epilepsy Drug Market Size
      • 2.1.1 Global Epilepsy Drug Revenue 2014-2025
      • 2.1.2 Global Epilepsy Drug Sales 2014-2025
    • 2.2 Epilepsy Drug Growth Rate by Regions
      • 2.2.1 Global Epilepsy Drug Sales by Regions
      • 2.2.2 Global Epilepsy Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Epilepsy Drug Sales by Manufacturers
      • 3.1.1 Epilepsy Drug Sales by Manufacturers
      • 3.1.2 Epilepsy Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Epilepsy Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Epilepsy Drug Revenue by Manufacturers
      • 3.2.1 Epilepsy Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Epilepsy Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Epilepsy Drug Price by Manufacturers
    • 3.4 Epilepsy Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Epilepsy Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Epilepsy Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Epilepsy Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Epilepsy Drug Sales by Product
    • 4.2 Global Epilepsy Drug Revenue by Product
    • 4.3 Epilepsy Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Epilepsy Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Epilepsy Drug by Countries
      • 6.1.1 North America Epilepsy Drug Sales by Countries
      • 6.1.2 North America Epilepsy Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Epilepsy Drug by Product
    • 6.3 North America Epilepsy Drug by End User

    7 Europe

    • 7.1 Europe Epilepsy Drug by Countries
      • 7.1.1 Europe Epilepsy Drug Sales by Countries
      • 7.1.2 Europe Epilepsy Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Epilepsy Drug by Product
    • 7.3 Europe Epilepsy Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Epilepsy Drug by Countries
      • 8.1.1 Asia Pacific Epilepsy Drug Sales by Countries
      • 8.1.2 Asia Pacific Epilepsy Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Epilepsy Drug by Product
    • 8.3 Asia Pacific Epilepsy Drug by End User

    9 Central & South America

    • 9.1 Central & South America Epilepsy Drug by Countries
      • 9.1.1 Central & South America Epilepsy Drug Sales by Countries
      • 9.1.2 Central & South America Epilepsy Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Epilepsy Drug by Product
    • 9.3 Central & South America Epilepsy Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Epilepsy Drug by Countries
      • 10.1.1 Middle East and Africa Epilepsy Drug Sales by Countries
      • 10.1.2 Middle East and Africa Epilepsy Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Epilepsy Drug by Product
    • 10.3 Middle East and Africa Epilepsy Drug by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Epilepsy Drug Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Eisai
      • 11.2.1 Eisai Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Eisai Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Eisai Epilepsy Drug Products Offered
      • 11.2.5 Eisai Recent Development
    • 11.3 Novartis
      • 11.3.1 Novartis Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Novartis Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Novartis Epilepsy Drug Products Offered
      • 11.3.5 Novartis Recent Development
    • 11.4 Sanofi
      • 11.4.1 Sanofi Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sanofi Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sanofi Epilepsy Drug Products Offered
      • 11.4.5 Sanofi Recent Development
    • 11.5 Union Chimique Belge
      • 11.5.1 Union Chimique Belge Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Union Chimique Belge Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Union Chimique Belge Epilepsy Drug Products Offered
      • 11.5.5 Union Chimique Belge Recent Development
    • 11.6 Abbott
      • 11.6.1 Abbott Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Abbott Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Abbott Epilepsy Drug Products Offered
      • 11.6.5 Abbott Recent Development
    • 11.7 GlaxoSmithKline
      • 11.7.1 GlaxoSmithKline Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 GlaxoSmithKline Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 GlaxoSmithKline Epilepsy Drug Products Offered
      • 11.7.5 GlaxoSmithKline Recent Development
    • 11.8 Sunovion Pharmaceuticals
      • 11.8.1 Sunovion Pharmaceuticals Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sunovion Pharmaceuticals Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sunovion Pharmaceuticals Epilepsy Drug Products Offered
      • 11.8.5 Sunovion Pharmaceuticals Recent Development
    • 11.9 Teva Pharmaceutical
      • 11.9.1 Teva Pharmaceutical Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Teva Pharmaceutical Epilepsy Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Teva Pharmaceutical Epilepsy Drug Products Offered
      • 11.9.5 Teva Pharmaceutical Recent Development

    12 Future Forecast

    • 12.1 Epilepsy Drug Market Forecast by Regions
      • 12.1.1 Global Epilepsy Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Epilepsy Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Epilepsy Drug Market Forecast by Product
      • 12.2.1 Global Epilepsy Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Epilepsy Drug Revenue Forecast by Product 2019-2025
    • 12.3 Epilepsy Drug Market Forecast by End User
    • 12.4 North America Epilepsy Drug Forecast
    • 12.5 Europe Epilepsy Drug Forecast
    • 12.6 Asia Pacific Epilepsy Drug Forecast
    • 12.7 Central & South America Epilepsy Drug Forecast
    • 12.8 Middle East and Africa Epilepsy Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Epilepsy Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizure.
      It is one of the most common neurological disorders worldwide, affecting people of all ages.
      The global Epilepsy Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Epilepsy Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Epilepsy Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Epilepsy Drug in these regions.
      This research report categorizes the global Epilepsy Drug market by top players/brands, region, type and end user. This report also studies the global Epilepsy Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Eisai
      Novartis
      Sanofi
      Union Chimique Belge
      Abbott
      GlaxoSmithKline
      Sunovion Pharmaceuticals
      Teva Pharmaceutical

      Market size by Product
      First Generation Drugs
      Second Generation Drugs
      Third Generation Drugs
      Market size by End User
      Hospital
      Research

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Epilepsy Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Epilepsy Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Epilepsy Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Epilepsy Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Epilepsy Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Epilepsy Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now